VCG
ANIK icon

Vantage Consulting Group’s Anika Therapeutics ANIK Stock Holding History

Vantage Consulting Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-590
Closed -$27K – 191
2020
Q4 		$27K Buy
+590
New +$22.4K ﹤0.01% 727

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $18.1B AUM 18.25% 1-Year Est. Return

Vantage Consulting Group's ANIK Position: Q1 2021 in Review

Vantage Consulting Group sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 590 shares — an estimated $27K sold.

Vantage Consulting Group first reported a position in ANIK in Q4 2020 and held it in 1 quarter. The position peaked at $27K in Q4 2020. 146 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

  • Vantage Consulting Group reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 590 Anika Therapeutics shares in Q1 2021, an estimated $27K.
  • Vantage Consulting Group first reported a position in Anika Therapeutics in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Anika Therapeutics position peaked at $27K in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.